Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma
Status:
Not yet recruiting
Trial end date:
2029-06-01
Target enrollment:
Participant gender:
Summary
To explore PFS, ORR (CR/CRu+PR), OS and side effects of piamprizumab combined with RMA in
newly diagnosed PCNSL, so as to clarify the value of piamprizumab combined with RMA in the
first-line treatment of PCNSL patients, and to clarify the clinical and biological factors
affecting the efficacy
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University